罗氏(RHHBY.US)减肥药CT-388明年推进后期试验挑战礼来、诺和诺德主导地位

智通财经09-22

智通财经APP获悉，罗氏(RHHBY.US)计划明年将实验性减肥药CT-388推进至后期试验阶段，以期在减肥药市场中挑战礼来(LLY.US)、诺和诺德(NVO.US)等头部企业。这款药物去年因早期研究披露的恶心、呕吐等副作用数据引发股价大幅下挫，但罗氏随后强调其副作用发生率与竞品相近，费用水平亦无显著差异。当前肥胖症市场由礼来和诺和诺德主导，预计到2030年年销售额将突破1000亿美元。为加速布局...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2569788388?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-22 17:31","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2569788388","market":"sh","top_or_hot":-1,"title":"罗氏(RHHBY.US)减肥药CT-388明年推进后期试验 挑战礼来、诺和诺德主导地位","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)计划明年将实验性减肥药CT-388推进至后期试验阶段，以期在减肥药市场中挑战礼来(LLY.US)、诺和诺德(NVO.US)等头部企业。这款药物去年因早期研究披露的恶心、呕吐等副作用数据引发股价大幅下挫，但罗氏随后强调其副作用发生率与竞品相近，费用水平亦无显著差异。当前肥胖症市场由礼来和诺和诺德主导，预计到2030年年销售额将突破1000亿美元。为加速布局...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1347947.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>罗氏(RHHBY.US)减肥药CT-388明年推进后期试验 挑战礼来、诺和诺德主导地位</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n罗氏(RHHBY.US)减肥药CT-388明年推进后期试验 挑战礼来、诺和诺德主导地位\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-22 17:31 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1347947.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，罗氏(RHHBY.US)计划明年将实验性减肥药CT-388推进至后期试验阶段，以期在减肥药市场中挑战礼来(LLY.US)、诺和诺德(NVO.US)等头部企业。这款药物去年因早期研究披露的恶心、呕吐等副作用数据引发股价大幅下挫，但罗氏随后强调其副作用发生率与竞品相近，费用水平亦无显著差异。当前肥胖症市场由礼来和诺和诺德主导，预计到2030年年销售额将突破1000亿美元。为加速布局...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1347947.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1232071149.USD","symbol_name":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1347947.html","article_id":"2569788388","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2569788388","pubTimestamp":1758533496,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，罗氏计划明年将实验性减肥药CT-388推进至后期试验阶段，以期在减肥药市场中挑战礼来、诺和诺德等头部企业。这款药物去年因早期研究披露的恶心、呕吐等副作用数据引发股价大幅下挫，但罗氏随后强调其副作用发生率与竞品相近，费用水平亦无显著差异。当前肥胖症市场由礼来和诺和诺德主导，预计到2030年年销售额将突破1000亿美元。截至上周五，罗氏股价收涨1.46%，年内累计涨幅约5.4%。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU2746668974.SGD":"MANULIFE DYNAMIC LEADERS \"AA\" (SGDHDG) ACC","LU1720051108.HKD":"ALLIANZ GLOBAL ARTIFICIAL INTELLIGENCE \"AT\" (HKD) ACC","SG9999014898.SGD":"United Global Quality Growth Fund Dis SGD","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","LU1917777945.USD":"安联专题基金Cl AT Acc","BK4007":"制药","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","BK4581":"高盛持仓","RHHBY":"罗氏控股","SG9999001176.USD":"United Global Healthcare Acc USD","LU2471134879.HKD":"INVESCO GLOBAL EQUITY INCOME ADVANTAGE \"A\" (HKD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","SG9999014880.SGD":"大华全球优质成长基金Acc SGD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0471298777.SGD":"Blackrock Nutrition A2 SGD-H","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SG9999015986.USD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (USD) ACC","03165":"华夏欧优股对冲","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","LU0786609619.USD":"高盛全球千禧一代股票组合Acc","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","SG9999014914.USD":"UNITED GLOBAL QUALITY GROWTH (USDHDG) INC","LU2108987350.USD":"UBS (LUX) EQUITY SICAV GLOBAL OPPORTUNITY SUSTAINABLE (USD) \"P\" (USD) ACC","LU2063271972.USD":"富兰克林创新领域基金","LU0823434740.USD":"BNP PARIBAS US GROWTH \"C\" (USD) INC","LU0385154629.USD":"贝莱德营养科学基金A2","SG9999015945.SGD":"LionGlobal Disruptive Innovation Fund A SGD","LU2602419157.SGD":"HSBC ISLAMIC GLOBAL EQUITY INDEX \"AC\" (SGD) ACC","LU1551013425.SGD":"Allianz Income and Growth Cl AMg2 DIS H2-SGD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","BK4588":"碎股"},"translate_title":"Roche (RHHBY.US) diet drug CT-388 advances late-stage trials next year to challenge the dominance of Eli Lilly and Novo Nordisk","themeId":"c8c015636e69da2c01039595706c31dc","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RHHBY":1.5,"03165":0.6},"content_text":"智通财经APP获悉，罗氏(RHHBY.US)计划明年将实验性减肥药CT-388推进至后期试验阶段，以期在减肥药市场中挑战礼来(LLY.US)、诺和诺德(NVO.US)等头部企业。这款药物去年因早期研究披露的恶心、呕吐等副作用数据引发股价大幅下挫，但罗氏随后强调其副作用发生率与竞品相近，费用水平亦无显著差异。当前肥胖症市场由礼来和诺和诺德主导，预计到2030年年销售额将突破1000亿美元。为加速布局，罗氏今年已与新西兰制药公司达成53亿美元合作协议，合作开发Zealand在研减肥药物，同时自身研发管线亦包含另一款在研减肥药物。CT-388与礼来明星产品Zepbound作用机制相似，通过激活GLP-1和GIP受体促进饱腹感、减少进食。罗氏还披露，CT-388若与Zealand Pharma的管线药物联用，可能形成“同类最佳”治疗方案，耐受性更优。截至上周五，罗氏股价收涨1.46%，年内累计涨幅约5.4%。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.9","shortVersion":"4.35.9","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2569788388","isCrawlerRequest":true}

罗氏(RHHBY.US)减肥药CT-388明年推进后期试验 挑战礼来、诺和诺德主导地位

精彩评论

罗氏(RHHBY.US)减肥药CT-388明年推进后期试验挑战礼来、诺和诺德主导地位